Researchers at Texas A&M University have engineered an injectable treatment designed to boost the production of ANP, a hormone renowned for safeguarding the heart post-myocardial infarction. The findings of this study are detailed in the journal Science.
Following a heart attack, the cardiac muscle sustains damage and must function under increased stress. In reaction, the body releases Atrial Natriuretic Peptide (ANP), a hormone that helps alleviate the strain on the heart muscle and shields tissues from progressive injury. Nevertheless, the inherent levels of this hormone are generally insufficient to engender meaningful recovery.
This novel injection addresses that deficiency. The therapeutic agent is administered into skeletal muscles, whereupon the cells temporarily receive “directions” to synthesize extra ANP. This hormone enters the bloodstream, reaches the heart, thereby reducing its operational burden and facilitating tissue repair. According to the research team, a single injection sustains the beneficial hormone output for several weeks.
“Essentially, this amounts to augmenting the heart’s innate defense system. The body already deploys ANP as a protective measure; we are simply facilitating an increased output of this substance during the crucial healing window,” the scientists stated.
The injection leverages self-amplifying RNA (saRNA) technology. Unlike standard RNA pharmaceuticals, these molecules possess the capability to temporarily replicate themselves inside the cell. This inherent property extends the therapeutic duration while requiring a smaller overall dose for treatment efficacy.
Even after surviving an initial heart attack, the heart frequently weakens over time due to scar tissue formation and the demise of some muscle mass. The study’s authors posit that elevating ANP levels in the initial weeks post-attack could mitigate scar development, preserve more viable tissue, and ultimately enhance long-term cardiac function.
This investigation builds upon preceding work from the same collective. Previously, the scientists devised a microneedle patch applied directly atop the heart surface to release tissue-regenerating hormones. The current methodology achieves a comparable outcome using a standard injection, circumventing the need for surgical placement.
About the Author
